{
    "id": "34178462",
    "revid": "17819300",
    "url": "https://en.wikipedia.org/wiki?curid=34178462",
    "title": "F-15063",
    "text": "F-15,063 is an orally active potential &lt;a href=\"antipsychotic\"&gt;antipsychotic&lt;/a&gt;, and an &lt;a href=\"antagonist\"&gt;antagonist&lt;/a&gt; at the &lt;a href=\"Dopamine%20receptor%20D2\"&gt;D2&lt;/a&gt;/&lt;a href=\"Dopamine%20receptor%20D3\"&gt;D3&lt;/a&gt; receptors, &lt;a href=\"partial%20agonist\"&gt;partial agonist&lt;/a&gt; at the &lt;a href=\"Dopamine%20receptor%20D4\"&gt;D4&lt;/a&gt; receptor, and agonist at the &lt;a href=\"5-HT1A%20receptor\"&gt;5-HT1A&lt;/a&gt; receptors. It has greater efficacy at the 5-HT1A receptors than other antipsychotics, such as &lt;a href=\"clozapine\"&gt;clozapine&lt;/a&gt;, &lt;a href=\"aripiprazole\"&gt;aripiprazole&lt;/a&gt;, and &lt;a href=\"ziprasidone\"&gt;ziprasidone&lt;/a&gt;. This greater efficacy may lead to enhanced antipsychotic properties, as antipsychotics that lack 5-HT1A affinity are associated with increased risk of &lt;a href=\"extrapyramidal%20symptoms\"&gt;extrapyramidal symptoms&lt;/a&gt;, and lack of activity against the negative symptoms of &lt;a href=\"schizophrenia\"&gt;schizophrenia&lt;/a&gt;.\nAs expression of &lt;a href=\"Immediate%20early%20gene\"&gt;immediate-early gene&lt;/a&gt; (IEG) in certain brain regions may represent markers of anti-psychotic activity, expression of immediate-early gene &lt;a href=\"mRNA\"&gt;mRNA&lt;/a&gt; in the &lt;a href=\"prefrontal%20cortex\"&gt;prefrontal cortex&lt;/a&gt; and &lt;a href=\"striatum\"&gt;striatum&lt;/a&gt; was measured. Treatment with F-15,063 resulted in induction of \"&lt;a href=\"c-fos\"&gt;c-fos&lt;/a&gt;\" and \"&lt;a href=\"fosB\"&gt;fosB&lt;/a&gt;\" mRNA expression in the prefrontal cortex. In the striatum, F-15,063 treatment resulted in induction of all \nIEGs studied (\"c-fos, fosB, &lt;a href=\"zif268\"&gt;zif268&lt;/a&gt;, &lt;a href=\"c-jun\"&gt;c-jun&lt;/a&gt;, &lt;a href=\"JUNB\"&gt;junB&lt;/a&gt;, &lt;a href=\"NOR1\"&gt;nor1&lt;/a&gt;, &lt;a href=\"nur77\"&gt;nur77&lt;/a&gt;, &lt;a href=\"Arc%20%28protein%29\"&gt;arc&lt;/a&gt;\").\nF-15,063 was tested in several animal models that predict antipsychotic activity to help determine the behavioral profile. Administration of F-15,063 blocked &lt;a href=\"amphetamine\"&gt;amphetamine&lt;/a&gt; and &lt;a href=\"ketamine\"&gt;ketamine&lt;/a&gt; induced hyperlocomotion, but did not affect baseline, spontaneous locomotor activity. In addition, F-15,063 did not produce &lt;a href=\"catalepsy\"&gt;catalepsy&lt;/a&gt;, a side effect of other antipsychotics, such as &lt;a href=\"haloperidol\"&gt;haloperidol&lt;/a&gt;. This inhibition of catalepsy is 5-HT1A receptor mediated, as pretreatment with the 5-HT1A antagonist &lt;a href=\"WAY-100635\"&gt;WAY-100635&lt;/a&gt; reinstated catalepsy. The level of catalepsy did not increase with chronic dosing, and there was no evidence for &lt;a href=\"serotonin%20syndrome\"&gt;serotonin syndrome&lt;/a&gt; at clinically relevant doses.\nPlasma levels of F-15,063 decreased seven-fold 4 hours after oral administration, and 25-fold after 8 hours. Despite this, there was still a high (65%) level of central D2 occupancy at 4 hours, and it retained its full antipsychotic potential at this time point. Even after 8 hours, F-15,063 still demonstrated some central D2 occupancy, and retained some antipsychotic activity."
}